Regeneronvs.United Therapeutics
REGN vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 3.3× larger than United Therapeutics by market cap; year to date, United Therapeutics leads (+9.3% vs −4.2%).
Side by side
| REGN | UTHR | |
|---|---|---|
| Market cap | $76.1B | $22.9B |
| Price | $746.54 | $549.16 |
| Today | +0.9% | +3.1% |
| Return YTD | −4.2% | +9.3% |
| Return 1Y | +31.2% | +18.7% |
| Since June 26, 2026 | +18.0% | +1.2% |
| P/E | 17.6 | 17.4 |
| P/S | 4.9 | 7.2 |
| P/B | 2.4 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More REGN & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.